tradingkey.logo

Biomerica Inc

BMRA
2.170USD
-0.080-3.56%
收盘 02/09, 16:00美东报价延迟15分钟
14.90M总市值
亏损市盈率 TTM

Biomerica Inc

2.170
-0.080-3.56%

关于 Biomerica Inc 公司

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.

Biomerica Inc简介

公司代码BMRA
公司名称Biomerica Inc
上市日期Mar 17, 1980
CEOIrani (Zackary S)
员工数量53
证券类型Ordinary Share
年结日Mar 17
公司地址17571 Von Karman Avenue
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92614
电话19493792875
网址https://biomerica.com/
公司代码BMRA
上市日期Mar 17, 1980
CEOIrani (Zackary S)

Biomerica Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
219.13K
+52500.00%
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
64.53K
+40000.00%
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
41.25K
+20000.00%
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
32.50K
+22500.00%
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
业务USD
名称
营收
占比
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%
地区USD
名称
营收
占比
Asia
670.00K
48.55%
United States
318.00K
23.04%
Europe
305.00K
22.10%
Middle East
85.00K
6.16%
South America
2.00K
0.14%
业务
地区
业务USD
名称
营收
占比
Clinical Lab
1.02M
74.20%
Contract Manufacturing
192.00K
13.91%
OTC
161.00K
11.67%
Physicians’ Office
3.00K
0.22%

股东统计

更新时间: 1月25日 周日
更新时间: 1月25日 周日
持股股东
股东类型
持股股东
持股股东
占比
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
其他
85.94%
持股股东
持股股东
占比
Irani (Zackary S)
7.26%
Barbieri (Allen)
2.23%
Lu (Gary)
2.14%
Moatazedi (David)
1.37%
Chin (Eric)
1.08%
其他
85.94%
股东类型
持股股东
占比
Individual Investor
15.59%
Investment Advisor
1.98%
Investment Advisor/Hedge Fund
0.76%
Hedge Fund
0.35%
Research Firm
0.03%
其他
81.28%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
61
94.32K
3.12%
-232.75K
2025Q3
66
109.78K
12.53%
+19.30K
2025Q2
64
90.48K
15.22%
-57.30K
2025Q1
68
147.78K
21.33%
-341.18K
2024Q4
67
244.57K
22.09%
-15.39K
2024Q3
66
259.96K
25.76%
-100.07K
2024Q2
66
360.04K
29.98%
-224.63K
2024Q1
64
584.66K
28.76%
-20.09K
2023Q4
60
562.02K
30.44%
-39.83K
2023Q3
60
602.09K
33.14%
-52.42K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Irani (Zackary S)
219.13K
7.43%
+52.50K
+31.51%
Dec 12, 2025
Barbieri (Allen)
67.29K
2.28%
+30.00K
+80.44%
Dec 12, 2025
Lu (Gary)
64.53K
2.19%
+40.00K
+163.05%
Dec 12, 2025
Moatazedi (David)
41.25K
1.4%
+20.00K
+94.12%
Dec 12, 2025
Chin (Eric)
10.00K
0.34%
--
--
Oct 17, 2025
Emerson (Jane)
30.13K
1.02%
+30.13K
--
Oct 17, 2025
The Vanguard Group, Inc.
21.13K
0.72%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
20.98K
0.71%
-680.00
-3.14%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
18.64K
0.63%
--
--
Sep 30, 2025
Coste (Catherine)
16.10K
0.55%
+10.63K
+194.10%
Dec 13, 2024
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
Apr 16, 2025
Merger
8→1
公告日期
除权除息日
类型
比率
Apr 16, 2025
Merger
8→1
KeyAI